+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Elafibranor (Genfit) Drug Overview 2019

  • PDF Icon


  • 15 Pages
  • July 2019
  • Region: Global
  • Pharma Intelligence
  • ID: 4846096
Drug Overview
Elafibranor (Genfit) is an oral peroxisome proliferator-activated receptor (PPAR) alpha-delta dual agonist. The medication activates PPAR-alpha and PPAR-delta, which control gene expression. Stimulating these receptors increases insulin sensitivity and fatty acid oxidation, which results in a reduction of fat buildup in the liver and leads to a decrease in fibrosis and inflammation. Elafibranor has also been shown to increase high-density lipoprotein levels, which may provide additional cardiovascular benefits.

Elafibranor has experienced mixed results in its Phase IIb GOLDEN trial due to the inclusion of non-alcoholic steatohepatitis (NASH) patients with Non-Alcoholic Fatty Liver Disease Activity Score (NAS) of 3 or above, rather than 4, which is usually required for NASH trials. This diluted the effect of the drug and likely contributed to the failure of elafibranor to meet the predefined primary endpoint of NASH resolution with no worsening fibrosis. However, a separate analysis that only included patients with a NAS score of 4 or above showed that significantly more patients in the 120mg elafibranor-treated group (19%) experienced the modified definition of NASH resolution compared to the placebo group (9%).

Table of Contents

  • Drug Overview
  • Product Profiles
  • elafibranor: Non-alcoholic steatohepatitis (NASH)

Figure 1: The author's drug assessment summary of elafibranor for NASH
Figure 2: The author's drug assessment summary of elafibranor for NASH
Figure 3: Elafibranor sales for NASH across the US and five major EU markets, by country, 2018–27
Table 1: Elafibranor drug profile
Table 2: Late-phase trials of elafibranor for NASH
Table 3: Elafibranor for NASH – SWOT analysis